High incidence of renal stones among hiv-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy

Clinical Infectious Diseases

Volumn 55, Issue 9, 2012, Pages 1262-1269

  Hamada, Yohei ^a   Nishijima, Takeshi ^a,c   Watanabe, Koji ^a,c   Komatsu, Hirokazu ^b   Tsukada, Kunihisa ^a   Teruya, Katsuji ^a   Gatanaga, Hiroyuki ^a,c   Kikuchi, Yoshimi ^a   Oka, Shinichi ^a,c  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR PLUS RITONAVIR;

ADULT; ARTICLE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INCIDENCE; KIDNEY CALCULI; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RETROSPECTIVE STUDIES; RITONAVIR;

EID: 84867535396     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis621     Document Type: Article

References (26)

1. Adolescents PoAGfAa. Panel on antiretroviral guidelines for adults and adolescents. guidelines for the use of antiretroviral agents in HIV- 1 infected adults and adolescents. Available at: http://www.aidsinfo. nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed 3 April 2012.
2. European AIDS Clinical Society. Guidelines for the clinical management and treatment of HIV infected adults in Europe. Available at: http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/ 1-treatment-of-hiv-infected-adults.pdf. Accessed 3 April 2012.
3. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011-9. (Pubitemid 38989366)
4. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53:323-32.
5. Chang HR, Pella PM. Atazanavir urolithiasis. N Engl J Med 2006; 355:2158-9.
6. Anderson PL, Lichtenstein KA, Gerig NE, Kiser JJ, Bushman LR. Atazanavir-containing renal calculi in an HIV-infected patient. AIDS 2007; 21:1060-2. (Pubitemid 46684345)
7. Nadler RB, Rubenstein JN, Eggener SE, Loor MM, Smith ND. The etiology of urolithiasis in HIV infected patients. J Urol 2003; 169:475-7. (Pubitemid 36132965)
8. Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavirassociated nephrolithiasis: cases from the US Food and drug administration's adverse event reporting system. AIDS 2007; 21:1215-8. (Pubitemid 46763296)
9. Couzigou C, Daudon M, Meynard JL, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 2007; 45:e105-8. (Pubitemid 47580370)
10. Rule AD, Bergstralh EJ, Melton LJ 3rd, Li X, Weaver AL, Lieske JC. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:804-11.
11. Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis 2004; 44:799-805. (Pubitemid 39445911)
12. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV medicine association of the infectious diseases society of America. Clin Infect Dis 2005; 40:1559-85. (Pubitemid 40720806)
13. The Japanese Ministry of Health, Labour, and Welfare. Guidelines for antiretroviral treatment for patients with HIV infection [in Japanese]. Available at: http://www.haart-support.jp/guideline2011.pdf. Accessed 3 April 2012.
14. Parmar MS. Kidney stones. BMJ 2004; 328:1420-4. (Pubitemid 38789199)
15. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145:247-54. (Pubitemid 46768608)
16. Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M. Ritonavirboosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS 2011; 25:1671-3.
17. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24:1667-78.
18. Albini L, Cesana BM, Motta D, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr 2012; 59:18-30.
19. Young J, Schafer J, Fux CA, et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012; 26:567-75.
20. Engeler DS, John H, Rentsch KM, Ruef C, Oertle D, Suter S. Nelfinavir urinary stones. J Urol 2002; 167:1384-5. (Pubitemid 34132100)
21. Feicke A, Rentsch KM, Oertle D, Strebel RT. Same patient, new stone composition: amprenavir urinary stone. Antivir Ther 2008; 13:733-4.
22. Doco-Lecompte T, Garrec A, Thomas L, Trechot P, May T, Rabaud C. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS 2004; 18:705-6. (Pubitemid 38393477)
23. Kaletra (lopinavir/ritonavir): full prescription information [package insert]. Barcelona, PR: Abbott Pharmaceuticals PR, 2012.
24. Reyataz (atazanavir sulfate): full prescription information [package insert]. Princeton, NJ: Bristol-Myers Squibb, 2012.
25. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277:145-53. (Pubitemid 27030184)
26. Rodriguez Novoa S, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006; 42:291-5. (Pubitemid 43054206)